StockNews.com started coverage on shares of Dynavax Technologies (NASDAQ:DVAX – Get Rating) in a research report released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the stock. JMP Securities lifted their target price on shares of Dynavax Technologies from $22.00 to $25.00 and gave the stock a market outperform rating in a research note on Friday, February 24th. HC Wainwright reduced their target price on shares of Dynavax Technologies from $28.00 to $27.00 and set a buy rating for the company in a research note on Friday, February 24th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $24.33.
Dynavax Technologies Price Performance
DVAX opened at $9.44 on Thursday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 4.79 and a beta of 1.45. The company has a quick ratio of 5.71, a current ratio of 6.11 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average price of $10.88 and a 200-day moving average price of $11.21. Dynavax Technologies has a twelve month low of $7.26 and a twelve month high of $17.48.
Insider Activity at Dynavax Technologies
Hedge Funds Weigh In On Dynavax Technologies
Several hedge funds have recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky grew its stake in Dynavax Technologies by 23.6% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 36,108 shares of the biopharmaceutical company’s stock valued at $385,000 after acquiring an additional 6,883 shares in the last quarter. Point72 Middle East FZE bought a new stake in Dynavax Technologies during the fourth quarter valued at approximately $53,000. State of Wyoming lifted its position in Dynavax Technologies by 151.9% during the fourth quarter. State of Wyoming now owns 19,918 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 12,011 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its position in Dynavax Technologies by 32.6% during the fourth quarter. Susquehanna Fundamental Investments LLC now owns 144,983 shares of the biopharmaceutical company’s stock valued at $1,543,000 after purchasing an additional 35,649 shares during the last quarter. Finally, Tang Capital Management LLC lifted its position in Dynavax Technologies by 200.0% during the fourth quarter. Tang Capital Management LLC now owns 300,000 shares of the biopharmaceutical company’s stock valued at $3,192,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 94.26% of the company’s stock.
About Dynavax Technologies
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.